GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Quick Ratio

Shield Therapeutics (LSE:STX) Quick Ratio : 2.64 (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Shield Therapeutics's quick ratio for the quarter that ended in Jun. 2023 was 2.64.

Shield Therapeutics has a quick ratio of 2.64. It generally indicates good short-term financial strength.

The historical rank and industry rank for Shield Therapeutics's Quick Ratio or its related term are showing as below:

LSE:STX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06   Med: 2.96   Max: 17.86
Current: 2.64

During the past 9 years, Shield Therapeutics's highest Quick Ratio was 17.86. The lowest was 0.06. And the median was 2.96.

LSE:STX's Quick Ratio is ranked better than
75.26% of 1075 companies
in the Drug Manufacturers industry
Industry Median: 1.34 vs LSE:STX: 2.64

Shield Therapeutics Quick Ratio Historical Data

The historical data trend for Shield Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Quick Ratio Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 3.97 1.30 1.71 4.20 0.81

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.86 4.20 2.16 0.81 2.64

Competitive Comparison of Shield Therapeutics's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Quick Ratio falls into.



Shield Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Shield Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(10.094-1.457)/10.639
=0.81

Shield Therapeutics's Quick Ratio for the quarter that ended in Jun. 2023 is calculated as

Quick Ratio (Q: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(26.101-2.695)/8.86
=2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics  (LSE:STX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Shield Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.